Laboratorios Farmaceuticos Rovi, S.A. (ROVI.MC)
EUR 50.9
(0.49%)
EUR 50.9
(0.49%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 492.28 Million EUR | -5.26% |
| 2022 | 519.61 Million EUR | 35.03% |
| 2021 | 384.82 Million EUR | 59.47% |
| 2020 | 241.3 Million EUR | 12.39% |
| 2019 | 214.7 Million EUR | 22.98% |
| 2018 | 174.59 Million EUR | 4.22% |
| 2017 | 167.51 Million EUR | 9.38% |
| 2016 | 153.14 Million EUR | 2.83% |
| 2015 | 148.93 Million EUR | 3.81% |
| 2014 | 143.46 Million EUR | 8.12% |
| 2013 | 132.69 Million EUR | 4.97% |
| 2012 | 126.41 Million EUR | 9.67% |
| 2011 | 115.26 Million EUR | 20.29% |
| 2010 | 95.82 Million EUR | 47.8% |
| 2009 | 64.83 Million EUR | -25.72% |
| 2008 | 87.28 Million EUR | 28.78% |
| 2007 | 67.78 Million EUR | 28.77% |
| 2006 | 52.63 Million EUR | -100.0% |
| 2005 | 7846.54 Billion EUR | 1328835.9% |
| 2004 | -590.52 Million EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 110.31 Million EUR | 28.77% |
| 2024 Q1 | 85.67 Million EUR | -38.17% |
| 2023 FY | 492.28 Million EUR | -5.26% |
| 2023 Q2 | 91.44 Million EUR | -27.44% |
| 2023 Q1 | 126.02 Million EUR | -28.6% |
| 2023 Q4 | 138.56 Million EUR | 1.69% |
| 2023 Q3 | 136.25 Million EUR | 49.01% |
| 2022 Q4 | 176.51 Million EUR | 51.14% |
| 2022 FY | 519.61 Million EUR | 35.03% |
| 2022 Q1 | 124.68 Million EUR | 4.73% |
| 2022 Q2 | 101.62 Million EUR | -18.49% |
| 2022 Q3 | 116.78 Million EUR | 14.92% |
| 2021 Q4 | 119.05 Million EUR | 6.28% |
| 2021 FY | 384.82 Million EUR | 59.47% |
| 2021 Q1 | 69.79 Million EUR | 4.57% |
| 2021 Q2 | 83.95 Million EUR | 20.28% |
| 2021 Q3 | 112.01 Million EUR | 33.43% |
| 2020 Q3 | 62.83 Million EUR | 10.61% |
| 2020 FY | 241.3 Million EUR | 12.39% |
| 2020 Q1 | 54.91 Million EUR | -6.09% |
| 2020 Q2 | 56.8 Million EUR | 3.45% |
| 2020 Q4 | 66.74 Million EUR | 6.22% |
| 2019 Q2 | 54.9 Million EUR | 17.87% |
| 2019 Q4 | 58.47 Million EUR | 6.81% |
| 2019 FY | 214.7 Million EUR | 22.98% |
| 2019 Q1 | 46.57 Million EUR | 3.5% |
| 2019 Q3 | 54.75 Million EUR | -0.28% |
| 2018 Q4 | 45 Million EUR | -0.5% |
| 2018 Q3 | 45.22 Million EUR | 10.8% |
| 2018 Q2 | 40.81 Million EUR | -6.28% |
| 2018 Q1 | 43.55 Million EUR | -5.97% |
| 2018 FY | 174.59 Million EUR | 4.22% |
| 2017 FY | 167.51 Million EUR | 9.38% |
| 2017 Q4 | 46.31 Million EUR | 22.92% |
| 2017 Q3 | 37.68 Million EUR | -10.98% |
| 2017 Q2 | 42.32 Million EUR | 2.76% |
| 2017 Q1 | 41.19 Million EUR | -1.12% |
| 2016 Q2 | 39.73 Million EUR | 10.1% |
| 2016 Q1 | 36.09 Million EUR | -10.08% |
| 2016 FY | 153.14 Million EUR | 2.83% |
| 2016 Q3 | 35.65 Million EUR | -10.27% |
| 2016 Q4 | 41.65 Million EUR | 16.84% |
| 2015 Q1 | 35.39 Million EUR | -11.46% |
| 2015 FY | 148.93 Million EUR | 3.81% |
| 2015 Q4 | 40.13 Million EUR | 13.57% |
| 2015 Q3 | 35.34 Million EUR | -7.15% |
| 2015 Q2 | 38.06 Million EUR | 7.52% |
| 2014 Q4 | 39.97 Million EUR | 19.48% |
| 2014 FY | 143.46 Million EUR | 8.12% |
| 2014 Q1 | 34.14 Million EUR | 2.09% |
| 2014 Q2 | 35.88 Million EUR | 5.11% |
| 2014 Q3 | 33.46 Million EUR | -6.76% |
| 2013 Q4 | 33.44 Million EUR | 4.0% |
| 2013 FY | 132.69 Million EUR | 4.97% |
| 2013 Q1 | 30.59 Million EUR | -50.39% |
| 2013 Q2 | 36.49 Million EUR | 19.27% |
| 2013 Q3 | 32.16 Million EUR | -11.87% |
| 2012 Q4 | 61.67 Million EUR | 98.77% |
| 2012 FY | 126.41 Million EUR | 9.67% |
| 2012 Q1 | 30.94 Million EUR | -44.37% |
| 2012 Q3 | 31.02 Million EUR | -8.17% |
| 2012 Q2 | 33.78 Million EUR | 9.18% |
| 2011 Q4 | 55.63 Million EUR | 100.0% |
| 2011 Q2 | 31.9 Million EUR | 15.01% |
| 2011 Q3 | 27.81 Million EUR | -12.8% |
| 2011 FY | 115.26 Million EUR | 20.29% |
| 2011 Q1 | 27.73 Million EUR | 8.11% |
| 2010 Q3 | 24.32 Million EUR | 2.57% |
| 2010 Q1 | 22.13 Million EUR | 0.0% |
| 2010 Q4 | 25.65 Million EUR | 5.48% |
| 2010 FY | 95.82 Million EUR | 47.8% |
| 2010 Q2 | 23.71 Million EUR | 7.15% |
| 2009 FY | 64.83 Million EUR | -25.72% |
| 2008 FY | 87.28 Million EUR | 28.78% |
| 2007 FY | 67.78 Million EUR | 28.77% |
| 2006 FY | 52.63 Million EUR | -100.0% |
| 2005 FY | 7846.54 Billion EUR | 1328835.9% |
| 2004 FY | -590.52 Million EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Atrys Health, S.A. | 52.61 Million EUR | -835.654% |
| Biotechnologies Assets SA | 3.45 Million EUR | -14136.77% |
| Oryzon Genomics S.A. | 13.94 Million EUR | -3429.453% |
| Pharma Mar, S.A. | 148.54 Million EUR | -231.416% |